论文部分内容阅读
本文介绍了纯化的2型登革(DEN-2)病毒灭活疫苗(PIV)原型的制备过程,并探讨了此法能否成为生产抗全部4种血清型DEN病毒疫苗的基本方法.作者从各型DEN病毒的分离株中筛选出能在Vero细胞中复制的适应株,感染转瓶培养的Vero细胞,维持液分加/不加人血清白蛋白,分别为批号WR-3和WR-4.收获培养5天的细胞病变率约为75%的上清液,超滤浓缩并离心纯化.结果发现纯化病毒只有一个血凝反应(HA)活力峰,约 95%的杂蛋白被去除.WR-3和WR-4病毒产量和回收率无明显差别,但WR-4的纯度是WR-3的5倍.
This article describes the preparation of a prototype of the purified dengue (DEN-2) virus inactivated vaccine (PIV) and examines whether this method can be a basic method of producing a vaccine against all 4 serotypes of DEN virus. The isolates of various types of DEN virus were screened for adapting strains capable of replicating in Vero cells, infected with Vero cells spiked in bottles and maintained with liquid addition / non-addition of serum albumin, batch numbers WR-3 and WR-4 The supernatant with about 75% cytopathicity was harvested for 5 days and concentrated by ultrafiltration and purified by centrifugation.The result showed that there was only one HA peak in the purified virus and about 95% of the hybrid protein was removed.WR -3 and WR-4 virus yield and recovery of no significant difference, but the purity of WR-4 WR-3 5 times.